Your support helps us to tell the story
From reproductive rights to climate change to Big Tech, The Independent is on the ground when the story is developing. Whether it's investigating the financials of Elon Musk's pro-Trump PAC or producing our latest documentary, 'The A Word', which shines a light on the American women fighting for reproductive rights, we know how important it is to parse out the facts from the messaging.
At such a critical moment in US history, we need reporters on the ground. Your donation allows us to keep sending journalists to speak to both sides of the story.
The Independent is trusted by Americans across the entire political spectrum. And unlike many other quality news outlets, we choose not to lock Americans out of our reporting and analysis with paywalls. We believe quality journalism should be available to everyone, paid for by those who can afford it.
Your support makes all the difference.Aspirin can reduce the chances of dying from bowel cancer by almost a third, research has shown.
Patients who took a daily dose of the pain killer for at least nine months after being diagnosed cut the likelihood of the disease killing them by 30%.
Taking aspirin for any length of time after diagnosis reduced the odds of dying from cancer by 23% compared with not taking aspirin at all.
The study looked at 4,500 bowel cancer patients in the Netherlands diagnosed between 1998 and 2007.
A quarter were not aspirin users, another quarter only took aspirin after diagnosis, while the remaining group took it both before and after developing cancer.
Lead researcher Dr Gerrit-Jan Liefers, from Leiden University Medical Centre in the Netherlands, said: "Our findings could have profound clinical implications. In this study, we showed the therapeutic effect of a widely-available, familiar drug that costs mere pennies per day.
"It's possible that some older people may have other health problems which mean that they are not well enough to have chemotherapy. Bowel cancer is more common in older people so these results could be a big advance in treatment of the disease, particularly in this group. But we need further research to confirm this."
His team is now planning a randomised controlled trial due to start later this year which will target the over-70s population.
The results are published today in the British Journal of Cancer, owned by Cancer Research UK.
Sarah Lyness, executive director policy and information at the charity, said: "This latest study adds to the growing evidence about the benefits of aspirin. The latest evidence suggests that the drug not only reduces the risk of dying from cancer, but can also help prevent the disease from developing in the first place.
"But we are not yet at the point where we would recommend people start taking aspirin to reduce their chances of developing cancer. There are still questions we need to answer about the side effects, such as internal bleeding, who might benefit most from taking aspirin, who might be harmed, what dose and how long people some people might want to take it for.
"Anyone thinking of taking aspirin to cut their risk of cancer should talk to their GP first. People with cancer should be aware that aspirin can increase the chances of complications before surgery or other cancer treatments such as chemotherapy and should discuss this with their specialist.
PA
Join our commenting forum
Join thought-provoking conversations, follow other Independent readers and see their replies
Comments